Sponsor Dossier
Roche Products
Sponsor Dossier for Roche Products. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACTEMRA
- Brand: ALECENSA
- Brand: CELLCEPT
- Brand: COLUMVI
- Brand: COTELLIC
- Brand: ENSPRYNG
- Brand: ERIVEDGE
- Brand: EVRYSDI
- Device (sponsor): Ophthalmic anaesthesia needle
- Device (sponsor): Ophthalmic implant handling forceps, single-use
- Device (sponsor): Ophthalmic anaesthesia needle
- Device (sponsor): Medication transfer set
- Device (sponsor): Self-care monitoring web-based application software
- Device (sponsor): Medication transfer set
- Device (sponsor): Medicine administration kit, percutaneous, non-medicated, single-use
- Device (sponsor): Contivue Implant with ITA (Insertion Tool Assembly - Implantable intraocular medication reservoir
About
Roche Products is an Australian Private Company with ABN 70000132865, registered in New South Wales with entity status Active.
Portfolio
Roche Products has 28 brands on the ARTG, of which 28 are indexable and 27 carry a Product Information document. 20 brands are PBS-listed, 18 have a PBAC outcome on record, and 18 have an AusPAR on record. Notable brands include ACTEMRA, ALECENSA, CELLCEPT, COLUMVI, COTELLIC, ENSPRYNG, ERIVEDGE, EVRYSDI, GAZYVA, HEMLIBRA, HERCEPTIN, ITOVEBI.
Therapeutic focus
— Oncology: 13 brands — Neurology: 3 brands — Haematology: 3 brands — Immunology: 2 brands — Ophthalmology: 2 brands — Infectious Disease: 2 brands — Renal: 1 brand — Respiratory: 1 brand — Rare Disease: 1 brand
PBS footprint
20 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2026-05-01, across 18 brands with a PBAC outcome on record. The latest AusPAR is 2025-08-12, across 18 brands with an AusPAR on record.